1887

Abstract

is the most common candidal pathogen, causing serious systemic disease in immunocompromised patients. Azoles are widely applied and largely effective; however, they are generally fungistatic and clinically resistant isolates are emerging increasingly. The present study provided evidence using a chequerboard technique that amiodarone is strongly synergistic with azoles against resistant , with mean fractional inhibitory concentration indices of 0.01 and high-percentage synergistic interactions of 1250 %. A time–kill study performed by both colony counting and a colorimetric reduction assay confirmed the synergistic interaction, with a ≥2 log decrease in c.f.u. ml compared with the corresponding azoles alone. These results suggest the possibility of supplementing azoles with amiodarone to treat resistant infections.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47651-0
2008-04-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/4/457.html?itemId=/content/journal/jmm/10.1099/jmm.0.47651-0&mimeType=html&fmt=ahah

References

  1. Afeltra, J., Vitale, R. G., Mouton, J. W. & Verweij, P. E. ( 2004; ). Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother 48, 1335–1343.[CrossRef]
    [Google Scholar]
  2. Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K. & Lincoln, L. ( 2006; ). Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 50, 2374–2383.[CrossRef]
    [Google Scholar]
  3. Barchiesi, F., Di Francesco, L. F., Compagnucci, P., Arzeni, D., Giacometti, A. & Scalise, G. ( 1998; ). In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother 41, 59–65.
    [Google Scholar]
  4. Baumgartner, C., Freydiere, A. M. & Gille, Y. ( 1996; ). Direct identification and recognition of yeast species from clinical material by using albicans ID and CHROMagar Candida plates. J Clin Microbiol 34, 454–456.
    [Google Scholar]
  5. CLSI ( 2002; ). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard M27–A2. Wayne, PA: Clinical Laboratory Standards Institute.
  6. Courchesne, W. E. ( 2002; ). Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther 300, 195–199.[CrossRef]
    [Google Scholar]
  7. Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H. & Heitman, J. ( 2002; ). Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21, 546–559.[CrossRef]
    [Google Scholar]
  8. Espinel-Ingroff, A., Barchiesi, F., Cuenca-Estrella, M., Pfaller, M. A., Rinaldi, M., Rodriguez-Tudela, J. L. & Verweij, P. E. ( 2005a; ). International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43, 3884–3889.[CrossRef]
    [Google Scholar]
  9. Espinel-Ingroff, A., Barchiesi, F., Cuenca-Estrella, M., Fothergill, A., Pfaller, M. A., Rinaldi, M., Rodriguez-Tudela, J. L. & Verweij, P. E. ( 2005b; ). Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol 43, 4535–4540.[CrossRef]
    [Google Scholar]
  10. Filler, S. G. & Sheppard, D. C. ( 2006; ). Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2, e129 [CrossRef]
    [Google Scholar]
  11. Fricker-Hidalgo, H., Vandapel, O., Duchesne, M. A., Mazoyer, M. A., Monget, D., Lardy, B., Lebeau, B., Freney, J., Ambroise-Thomas, P. & Grillot, R. ( 1996; ). Comparison of the new API Candida system to the ID 32C system for identification of clinically important yeast species. J Clin Microbiol 34, 1846–1848.
    [Google Scholar]
  12. Ghannoum, M. A., Fu, Y., Ibrahim, A. S., Mortara, L. A., Shafiq, M. C., Edwards, J. E., Jr & Criddle, R. S. ( 1995; ). In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 39, 2459–2465.[CrossRef]
    [Google Scholar]
  13. Girmenia, C., Venditti, M. & Martino, P. ( 2003; ). Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagn Microbiol Infect Dis 46, 227–231.[CrossRef]
    [Google Scholar]
  14. Gupta, S. S., Ton, V. K., Beaudry, V., Rulli, S., Cunningham, K. & Rao, R. ( 2003; ). Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 278, 28831–28839.[CrossRef]
    [Google Scholar]
  15. Klepser, M. E., Ernst, E. J., Lewis, R. E., Ernst, M. E. & Pfaller, M. A. ( 1998; ). Influence of test conditions on antifungal time–kill curve results: proposal for standardized methods. Antimicrob Agents Chemother 42, 1207–1212.
    [Google Scholar]
  16. Kuhn, D. M., Chandra, J., Mukherjee, P. K. & Ghannoum, M. A. ( 2002; ). Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 70, 878–888.[CrossRef]
    [Google Scholar]
  17. Kuhn, D. M., Balkis, M., Chandra, J., Mukherjee, P. K. & Ghannoum, M. A. ( 2003; ). Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 41, 506–508.[CrossRef]
    [Google Scholar]
  18. Lewis, R. E. & Kontoyiannis, D. P. ( 2005; ). Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56, 887–892.[CrossRef]
    [Google Scholar]
  19. Meletiadis, J., Mouton, J. W., Meis, J. F. & Verweij, P. E. ( 2003; ). In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47, 106–117.[CrossRef]
    [Google Scholar]
  20. Morschhäuser, J. ( 2002; ). The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587, 240–248.[CrossRef]
    [Google Scholar]
  21. Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A. & Ghannoum, M. A. ( 2005; ). Combination treatment of invasive fungal infections. Clin Microbiol Rev 18, 163–194.[CrossRef]
    [Google Scholar]
  22. Nicolay, J. P., Bentzen, P. J., Ghashghaeinia, M., Wieder, T. & Lang, F. ( 2007; ). Stimulation of erythrocyte cell membrane scrambling by amiodarone. Cell Physiol Biochem 20, 1043–1050.[CrossRef]
    [Google Scholar]
  23. Odds, F. C. ( 2003; ). Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52, 1 [CrossRef]
    [Google Scholar]
  24. Pfaller, M. A., Houston, A. & Coffmann, S. ( 1996; ). Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei and Candida (Torulopsis) glabrata. J Clin Microbiol 34, 58–61.
    [Google Scholar]
  25. Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S. & Diekema, D. J. ( 2005; ). In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 43, 3807–3810.[CrossRef]
    [Google Scholar]
  26. Quan, H., Cao, Y. Y., Xu, Z., Zhao, J. X., Gao, P. H., Qin, X. F. & Jiang, Y. Y. ( 2006; ). Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob Agents Chemother 50, 1096–1099.[CrossRef]
    [Google Scholar]
  27. Ramage, G., Vande Walle, K., Wickes, B. L. & López-Ribot, J. L. ( 2001; ). Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45, 2475–2479.[CrossRef]
    [Google Scholar]
  28. Ribeiro, M. A. & Paula, C. R. ( 2007; ). Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication? Diagn Microbiol Infect Dis 57, 71–75.[CrossRef]
    [Google Scholar]
  29. Tam, V. H., Schilling, A. N., Lewis, R. E., Melnick, D. A. & Boucher, A. N. ( 2004; ). Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48, 4315–4321.[CrossRef]
    [Google Scholar]
  30. Te Dorsthorst, D. T., Verweij, P. E., Meis, J. F., Punt, N. C. & Mouton, J. W. ( 2002; ). Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother 46, 702–707.[CrossRef]
    [Google Scholar]
  31. Te Dorsthorst, D. T., Verweij, P. E., Meis, J. F., Punt, N. C. & Mouton, J. W. ( 2004; ). In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother 48, 2007–2013.[CrossRef]
    [Google Scholar]
  32. Vassallo, P. & Trohman, R. G. ( 2007; ). Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298, 1312–1322.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47651-0
Loading
/content/journal/jmm/10.1099/jmm.0.47651-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error